BioCentury | Oct 4, 1999
Company News

Antex, SmithKline deal

...The companies restructured their 1996 agreement to develop infectious disease vaccines, dissolving their joint venture, MicroCarb...
BioCentury | Sep 9, 1996
Company News

MicroCarb infectious diseases/aids news

...the company began trading on the OTC Bulletin Board on Tuesday under the symbol ANTX. MicroCarb Inc....
BioCentury | Aug 12, 1996
Clinical News

MicroCarb regulatory update

MicroCarb Inc. (CARB), Gaithersburg, Md. Business: Infectious diseases/AIDS CARB received U.S. Patent No. 5,512,282 covering monospecific polyclonal antibodies to Shiga-like toxins. The patent covers the production and use of antibodies that detect Shiga-like toxins or...
BioCentury | Jul 1, 1996
Clinical News

Vaccine to interrupt use of nutrients by bacteria: CARB completed Phase I testing

MicroCarb Inc. (CARB), Gaithersburg, Md. Product: Vaccine to interrupt use of nutrients by bacteria Indication: Campylobacter enteritis, which causes gastroenteritis and diarrhea Status: CARB completed Phase I testing in 30 volunteers, demonstrating safety and immunogenicity....
BioCentury | May 13, 1996
Company News

MicroCarb, SmithKline deal

...excluding royalties. SmithKline is responsible for clinical development, manufacturing and worldwide marketing of the vaccines. MicroCarb Inc....
BioCentury | Mar 11, 1996
Company News

MicroCarb, Pasteur-Merieux Serums et Vaccins deal

...influenzae otitis media vaccine. Otitis media is a common ear infection in infants and children. MicroCarb Inc....
BioCentury | Jul 17, 1995
Clinical News

MicroCarb regulatory update

...the patent is applicable to a range of bacteria including Helicobacter pylori and Chlamydia trachomatis. MicroCarb Inc....
BioCentury | Jul 3, 1995
Clinical News

Killed whole-cell Campylobacter vaccine: Began Phase I testing, under a CRADA with the U.S. Navy, in 20 volunteers, with 10 more volunteers as a control group

MicroCarb Inc. (CARB), Gaithersburg, Md. Product: Killed whole-cell Campylobacter vaccine Indication: Prevent gastroenteritis and diarrhea from Campylobacter infection Status: Began Phase I testing, under a CRADA with the U.S. Navy, in 20 volunteers, with 10...
BioCentury | Jan 3, 1995
Company News

MicroCarb deal

...researching vaccines for Moraxella catarrhalis and Streptococcus pneumoniae, the two other agents of the infection. MicroCarb Inc....
BioCentury | Dec 5, 1994
Company News

MicroCarb deal

...and diarrhea caused by enteropathogenic Campylobacter. CARB said the oral vaccine will provide mucosal immunity. MicroCarb Inc....
Items per page:
1 - 10 of 12
BioCentury | Oct 4, 1999
Company News

Antex, SmithKline deal

...The companies restructured their 1996 agreement to develop infectious disease vaccines, dissolving their joint venture, MicroCarb...
BioCentury | Sep 9, 1996
Company News

MicroCarb infectious diseases/aids news

...the company began trading on the OTC Bulletin Board on Tuesday under the symbol ANTX. MicroCarb Inc....
BioCentury | Aug 12, 1996
Clinical News

MicroCarb regulatory update

MicroCarb Inc. (CARB), Gaithersburg, Md. Business: Infectious diseases/AIDS CARB received U.S. Patent No. 5,512,282 covering monospecific polyclonal antibodies to Shiga-like toxins. The patent covers the production and use of antibodies that detect Shiga-like toxins or...
BioCentury | Jul 1, 1996
Clinical News

Vaccine to interrupt use of nutrients by bacteria: CARB completed Phase I testing

MicroCarb Inc. (CARB), Gaithersburg, Md. Product: Vaccine to interrupt use of nutrients by bacteria Indication: Campylobacter enteritis, which causes gastroenteritis and diarrhea Status: CARB completed Phase I testing in 30 volunteers, demonstrating safety and immunogenicity....
BioCentury | May 13, 1996
Company News

MicroCarb, SmithKline deal

...excluding royalties. SmithKline is responsible for clinical development, manufacturing and worldwide marketing of the vaccines. MicroCarb Inc....
BioCentury | Mar 11, 1996
Company News

MicroCarb, Pasteur-Merieux Serums et Vaccins deal

...influenzae otitis media vaccine. Otitis media is a common ear infection in infants and children. MicroCarb Inc....
BioCentury | Jul 17, 1995
Clinical News

MicroCarb regulatory update

...the patent is applicable to a range of bacteria including Helicobacter pylori and Chlamydia trachomatis. MicroCarb Inc....
BioCentury | Jul 3, 1995
Clinical News

Killed whole-cell Campylobacter vaccine: Began Phase I testing, under a CRADA with the U.S. Navy, in 20 volunteers, with 10 more volunteers as a control group

MicroCarb Inc. (CARB), Gaithersburg, Md. Product: Killed whole-cell Campylobacter vaccine Indication: Prevent gastroenteritis and diarrhea from Campylobacter infection Status: Began Phase I testing, under a CRADA with the U.S. Navy, in 20 volunteers, with 10...
BioCentury | Jan 3, 1995
Company News

MicroCarb deal

...researching vaccines for Moraxella catarrhalis and Streptococcus pneumoniae, the two other agents of the infection. MicroCarb Inc....
BioCentury | Dec 5, 1994
Company News

MicroCarb deal

...and diarrhea caused by enteropathogenic Campylobacter. CARB said the oral vaccine will provide mucosal immunity. MicroCarb Inc....
Items per page:
1 - 10 of 12